Detecting Vascular-Targeting Effects of the Hypoxic Cytotoxin Tirapazamine in Tumor Xenografts Using Magnetic Resonance Imaging

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 3, 2009, Pages 957-965

  Bains, Lauren J ^a   Baker, Jennifer H E ^b   Kyle, Alastair H ^b   Minchinton, Andrew I ^b   Reinsberg, Stefan A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Dynamic contrast enhanced MRI; Fiducial marker; Hypoxic cytotoxins; Immunohistochemistry; Tumor mapping; Vascular dysfunction; Vascular shutdown

Indexed keywords

DYNAMIC CONTRAST-ENHANCED MRI; FIDUCIAL MARKER; HYPOXIC CYTOTOXINS; IMMUNOHISTOCHEMISTRY; VASCULAR DYSFUNCTION; VASCULAR SHUTDOWN;

BIOLOGICAL MATERIALS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; ONCOLOGY;

TUMORS;

GADOLINIUM PENTETATE; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HCT116; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; HISTOPATHOLOGY; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLOOD VOLUME; BLOOD VOLUME DETERMINATION; CELL HYPOXIA; CONTRAST MEDIA; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED NOD; MICE, SCID; NECROSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROSTHESES AND IMPLANTS; RADIATION-SENSITIZING AGENTS; REGIONAL BLOOD FLOW; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES;

EID: 67049107492     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.068     Document Type: Article

References (22)

1. Gray L., Conger A., Ebert M., Hornsey S., and Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
2. Marcu L., and Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol 1 (2006) 71-79
3. Anderson R., Shinde S., Hay M., Gamage S., and Denny W. Activation of 3-amino1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125 (2003) 748-756
4. Zeman E., Hirst V., Lemmon M., and Brown J. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12 (1988) 209-218
5. Dorie M., Menke D., and Brown J. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys 28 (1994) 145-150
6. Durand R., and Olive P. Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 22 (1992) 689-692
7. Durand R., and Olive P. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 5 (1997) 213-219
8. Hicks K., Fleming Y., Siim B., Koch C., and Wilson W. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 42 (1998) 641-649
9. Kyle A., and Minchinton A. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43 (1999) 213-220
10. Cardenas-Navia L., Secomb T., and Dewhirst M. Effects of fluctuating oxygenation on tirapazamine efficacy: Theoretical predictions. Int J Radiat Oncol Biol Phys 67 (2007) 581-586
11. Huxham L.A., Kyle A.H., Baker J.H.E., McNicol K.L., and Minchinton A.I. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol 78 (2006) 138-145
12. Huxham L., Kyle A., Baker J., McNicol K., and Minchinton A. Exploring vascular dysfunction caused by tirapazamine. Microvasc Res 75 (2008) 247-255
13. Galbraith S.M., Maxwell R.J., Lodge M.A., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
14. Robinson S.P., McIntyre D.J.O., Checkley D., et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88 (2003) 1592-1597
15. McPhail L.D., McIntyre D.J.O., Ludwig C., et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by DCE-MRI, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8 (2006) 199-206
16. Janssen H., Ljungkvist A., Rijken P., et al. Thymidine analogues to assess microperfusion in human tumors. Int J Radiat Oncol Biol Phys 62 (2005) 1169-1175
17. Kyle A., Huxham L., Baker J., Burston H., and Minchinton A. Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Res 63 (2003) 5707-5711
18. Kyle A., Huxham L., Yeoman D., and Minchinton A. Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin Cancer Res 13 (2007) 2804-2810
19. Abramoff M.D., Magelhaes P.J., and Ram S.J. Image processing with ImageJ. Biophotonics International 11 (2004) 36-42
20. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 (1999) 223-232
21. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med 17 (1991) 357-367
22. 18F-misonidazole PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine. J Clin Oncol 24 (2006) 2098-2104